Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRADA II study of atazanavir + dolutegravir + lamivudine maintenance therapy in HIV-1 infection
2014-004488-19Phase 2Terminated
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of atazanavir, dolutegravir and lamivudine in human immunodeficiency virus infection (HIV) and Human immunodeficiency virus infection type 1, sponsored by Radboud University Medical Center. Primary endpoints: Atazanavir pharmacokinetics and Dolutegravir pharmacokinetics. Started Jan 2015; status: terminated.
02
Drugs
atazanavirdolutegravirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2014-004488-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004488-19.